Lat­est news on BioN­Tech's Fri­day buy­out; Un­pack­ing Sarep­ta’s Duchenne da­ta; Pfiz­er’s post-Covid plans; Eli Lil­ly, As­traZeneca's gene edit­ing deals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With earn­ings sea­sons in full swing, the End­points team worked hard to stay on top of Big Phar­ma’s lat­est up­dates as well as break­ing news. Don’t miss our analy­sis on what a stand­ing ova­tion-wor­thy da­ta read­out at ES­MO means for fu­ture clin­i­cal tri­als, the FDA’s shift to­ward ask­ing for more over­all sur­vival da­ta and a Q&A about biotech in­ter­ests on Capi­tol Hill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER